Healthcare / Drug Manufacturers - Specialty & GenericJakarta
$272.00
-2.00 (-0.73%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $116.7B · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$228.5B
P/E
6.5x
↓EV/EBITDA
7.4x
↓ROE
6.8%
↑Gross Margin
52.3%
↑Debt/Equity
1.70
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.0%
FCF CAGR
-9.5%
FCF margin
12.4%
FCF / Net income
4.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $940.88B · net income $28.03B · FCF $116.73B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $940.88B | $940.88B | $744.69B | $1003.57B | $1168.47B |
| Net Income | $28.03B | $28.03B | $-285.07B | $7.87B | $28.07B |
| EBITDA | $109.57B | $109.57B | $-282.91B | $88.38B | $118.67B |
| EPS | 33.00 | 33.00 | -339.00 | 9.00 | 33.00 |
| Gross Margin | 52.3% | 52.3% | 36.3% | 50.6% | 50.0% |
| Operating Margin | 9.3% | 9.3% | -32.1% | 6.7% | 8.1% |
| Net Margin | 3.0% | 3.0% | -38.3% | 0.8% | 2.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.70 | 1.70 | 1.97 | 1.22 | 1.12 |
| Current Ratio | 2.10 | 2.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $116.73B | $116.73B | $126.08B | $32.10B | $157.61B |
| Returns | |||||
| ROE | 6.8% | 6.8% | -75.1% | 1.2% | 3.7% |
| Valuation | |||||
| P/E | 6.48 | 6.48 | — | 68.89 | 20.61 |
| EV/EBITDA | 7.43 | 7.43 | — | 14.23 | 10.68 |
| P/B | 0.55 | 0.55 | 0.70 | 0.79 | 0.76 |
| Growth & Yield | |||||
| Revenue Growth | 26.3% | 26.3% | -25.8% | -14.1% | — |
| EPS Growth | 109.7% | 109.7% | -3866.7% | -72.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-9.9%
EPS terminal req.
$24.14
Spread vs growth
119.6%
5Y implied EPS CAGR
-2.4%
EPS terminal req.
$29.20
Spread vs growth
112.1%
10Y implied EPS CAGR
3.6%
EPS terminal req.
$47.03
Spread vs growth
106.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-339.00 → 33.00
Residual
+3.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.